Tyloxapol

Indications

Tyloxapol is primarily indicated for use as an inhaled surfactant that facilitates the liquefaction and clearance of bronchopulmonary secretions comprised of mucus and pus. It is typically administered via a nebulized solution or directly through a stream of oxygen. Furthermore, Tyloxapol has been explored for potential applications in treating conditions such as cystic fibrosis and in pediatric patient populations.

Pharmacodynamics

As a surfactant, Tyloxapol plays a crucial role in aiding the liquefaction and removal of mucopurulent bronchopulmonary secretions. Additionally, Tyloxapol has the capacity to inhibit plasma lipolytic activity, thereby preventing the breakdown of triglyceride-rich lipoproteins.

Mechanism of Action

Tyloxapol, when administered intraperitoneally, effectively inhibits plasma lipolytic activity, thereby impeding the catabolism of triglyceride-rich lipoproteins. Furthermore, it functions as an inhibitor of lipoprotein lipase, consequently preventing the cellular uptake of triglycerides.